# How Genentech Engineered Antibodies to Block the Bv8 Protein

> This patent details specific genetic blueprints for creating antibodies that target and neutralize Bv8, a protein often associated with tumor growth and inflammation.

- **Patent:** US 9266948
- **Original title:** Anti-Bv8 antibodies and uses thereof
- **Owner:** Genentech Inc
- **Granted:** 2016
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical

## What it does

The patent claims the specific genetic sequences (nucleic acids) required to manufacture antibodies that bind to the Bv8 protein. These antibodies work by attaching to the Bv8 molecule, effectively neutralizing its ability to interact with its receptors in the body. By defining the exact amino acid sequences for the six hypervariable regions (HVRs)—the parts of the antibody that act like a lock to the protein's key—the patent provides a precise recipe for creating these therapeutic molecules. These sequences are then packaged into vectors and host cells, which act as biological factories to produce the antibodies at scale.

## What it does NOT cover

- Does not cover antibodies that bind to proteins other than Bv8.
- Does not cover the clinical use or medical treatment methods for patients using these antibodies.
- Does not cover antibodies with hypervariable region sequences that deviate from the specific amino acid patterns defined in the claims.
- Does not cover the Bv8 protein itself, only the synthetic antibodies designed to bind to it.

## The clever bit

The invention identifies the precise, highly specific amino acid configurations in the hypervariable regions that allow an antibody to bind to Bv8 with high affinity, effectively turning off a signaling pathway that tumors rely on.

## Real-world examples

1. Experimental cancer therapies targeting tumor-associated angiogenesis
2. Biological research tools for studying Bv8 signaling pathways

## Why it matters

Bv8 is a protein linked to the growth of blood vessels in tumors, a process known as angiogenesis. By blocking this protein, researchers aim to starve tumors of the blood supply they need to grow and spread. This patent represents a foundational step in developing targeted biological therapies for cancer and inflammatory diseases.

## Frequently asked questions

### What does How Genentech Engineered Antibodies to Block the Bv8 Protein cover?

This patent details specific genetic blueprints for creating antibodies that target and neutralize Bv8, a protein often associated with tumor growth and inflammation.

### Who owns patent US 9266948?

Genentech Inc owns this patent, granted in 2016.

### When does this patent expire?

This patent is expected to expire on February 23, 2036, when the invention enters the public domain.

### What problem does this patent solve?

Bv8 is a protein linked to the growth of blood vessels in tumors, a process known as angiogenesis. By blocking this protein, researchers aim to starve tumors of the blood supply they need to grow and spread. This patent represents a foundational step in developing targeted biological therapies for cancer and inflammatory diseases.

### What does this patent NOT cover?

Does not cover antibodies that bind to proteins other than Bv8.

**Full plain-English explainer:** https://patentbrief.org/patent/us/9266948/kadcyla-t-dm1

**Original patent:** https://patents.google.com/patent/US9266948

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._